• ENGLISH
  • FRANCAIS
  • Services
    • Services Overview
    • Clinical Trial Operations
      • Protocol Development and Study Design
      • Feasibility and Study Start Up
      • Patient Recruitment
      • Project Management
      • Clinical Operations
      • Centralized Monitoring
      • Decentralized Clinical Trials (DCT)
      • Centralized eTMF
      • Medical Services
    • Regulatory and Drug Development Consulting
      • Clinical Strategy
      • Nonclinical
      • Chemistry, Manufacturing, and Controls (CMC)
      • Regulatory Affairs
      • GxP Strategy Consulting
      • Publishing and Submissions
      • Medical Writing
    • Government and Public Health Services
    • Biometrics
      • Biostatistics and Statistical Programming
      • Data Management
    • Clinical Pharmacology Modeling Simulation
      • Clinical Pharmacology Integrated Drug Development
      • Model Informed Dose & Drug Development (MIDD)
      • Pharmacometrics (PMx), Pharmacokinetics, Pharmacodynamics (PK/PD)
      • DMPK and Translational Discovery and Development
  • Therapeutic Expertise
    • Therapeutic Expertise Overview
    • By Subject
      • Oncology and Hematology
      • Rare Diseases and Orphan Drugs
      • Infectious Disease and Vaccine
      • Cell and Gene Therapy
      • Central Nervous System
      • Autoimmune and Inflammation
      • Allergy and Asthma
    • By Phase
  • Company
    • About Us
    • History
    • News
    • Events
    • Leadership
    • Mission, Vision, Values
  • Resources
    • Resource Library
    • Blog
  • Careers
    • Careers Overview
    • Job Listings
    • CRA Academy and Fellows Program
  • Contact Us
    • Contact Us
    • Request for Proposal
  • ENGLISH
  • FRANCAIS
  • Services
    • Services Overview
    • Clinical Trial Operations
      • Protocol Development and Study Design
      • Feasibility and Study Start Up
      • Patient Recruitment
      • Project Management
      • Clinical Operations
      • Centralized Monitoring
      • Decentralized Clinical Trials (DCT)
      • Centralized eTMF
      • Medical Services
    • Regulatory and Drug Development Consulting
      • Clinical Strategy
      • Nonclinical
      • Chemistry, Manufacturing, and Controls (CMC)
      • Regulatory Affairs
      • GxP Strategy Consulting
      • Publishing and Submissions
      • Medical Writing
    • Government and Public Health Services
    • Biometrics
      • Biostatistics and Statistical Programming
      • Data Management
    • Clinical Pharmacology Modeling Simulation
      • Clinical Pharmacology Integrated Drug Development
      • Model Informed Dose & Drug Development (MIDD)
      • Pharmacometrics (PMx), Pharmacokinetics, Pharmacodynamics (PK/PD)
      • DMPK and Translational Discovery and Development
  • Therapeutic Expertise
    • Therapeutic Expertise Overview
    • By Subject
      • Oncology and Hematology
      • Rare Diseases and Orphan Drugs
      • Infectious Disease and Vaccine
      • Cell and Gene Therapy
      • Central Nervous System
      • Autoimmune and Inflammation
      • Allergy and Asthma
    • By Phase
  • Company
    • About Us
    • History
    • News
    • Events
    • Leadership
    • Mission, Vision, Values
  • Resources
    • Resource Library
    • Blog
  • Careers
    • Careers Overview
    • Job Listings
    • CRA Academy and Fellows Program
  • Contact Us
    • Contact Us
    • Request for Proposal
  1. Home
  2. Services
  3. Clinical Pharmacology Modeling Simulation
  4. Pharmacometrics (PMx), Pharmacokinetics, Pharmacodynamics (PK/PD)
  5. Population Pharmacokinetics (popPK)
    • Data Management, Programming, and CDISC Dataset Creation
    • Noncompartmental PK Analysis (NCA)
    • Population Pharmacokinetics (popPK)

Population Pharmacokinetics (popPK)

  • Pharmacometrics (PMx), Pharmacokinetics, Pharmacodynamics (PK/PD)
  • Data Management, Programming, and CDISC Dataset Creation
  • Noncompartmental PK Analysis (NCA)
  • Population Pharmacokinetics (popPK)

Population PK (popPK) analyses are a crucial aspect of almost all drug development programs. Because of the growing emphasis placed on popPK analyses by regulatory authorities, and the wealth of information that these analyses provide, it is more important than ever to consider how popPK fits into your own drug development program.

Allucent has an expert team of pharmacometricians who take complex population PK analyses and distill them into the critical insights that drive common-sense drug development. Population PK analysis can be completed during early to mid-stage clinical development or at later stages of development to fit your program needs.

What is Population PK?

Population pharmacokinetics, also referred to as population PK or popPK, is used to understand the variability in drug concentrations among individuals in a group of interest (the “population”). Patient characteristics (“covariates”), such as age, disease state, demographics, sex, concomitant medications, or presence of renal or hepatic impairment, can affect a drug’s pharmacokinetics (PK) and pharmacodynamics (PD). Understanding this variability can help establish a robust PK/PD profile and inform safe and effective dosing regimens.

PopPK analysis involves collecting sparse PK samples (i.e., drug concentration data) from many patients and often across multiple clinical studies, and then building mathematical models to describe those data. Using sparse PK sampling, only a limited number of samples are taken from any given patient. With appropriate sampling design and model selection, the resulting PK data can be pooled and analyzed to support conclusions about PK variability and the influence of covariates.

Population PK Services:

  • Expert advice on study design, including protocol and analysis plan development
  • NONMEM datasets
  • Population PK model generation, development, and refinement
  • Identification & confirmation of predictive covariates
  • Modeling & simulation to support population PK/PD
  • Parallel NONMEM to decrease run time for complex models
  • Dose selection and justification
  • Exposure-response analysis
  • Concentration QT (cQT) modeling
  • Submission-ready population PK report writing

Contact Us

Let us partner with your team on bringing new therapies to light. Get in touch to get started.

CONTACT US

  • Services
    • Clinical Trial Operations
    • Regulatory and Drug Development Consulting
    • Government and Public Health Services
    • Biometrics
    • Clinical Pharmacology Modeling Simulation
  • Therapeutic Expertise
    • Oncology and Hematology
    • Rare Diseases and Orphan Drugs
    • Infectious Disease and Vaccine
    • Cell and Gene Therapy
    • Central Nervous System
    • Autoimmune and Inflammation
    • Allergy and Asthma
  • Company
    • About Us
    • News
    • Events
  • Privacy Policy
  • English
  • Francais

© 2023 Allucent. All rights

North American Headquarters
2000 Centregreen Way
Suite 300
Cary, North Carolina 27513
+1 919-361-2286

United Kingdom Headquarters
1st Floor, One Station Square,
Bracknell, Berkshire
RG12 1QB United Kingdom
T: +44 (0) 1344 891121
F: +44 (0) 1344 890335

European Headquarters
Stationsplein Noord-Oost 438
1117 CL Schiphol
The Netherlands
+31 20-4350-580